Skip to main content
Back
CRNX logo

Crinetics Pharmaceuticals, Inc.

Data quality: 100%
Oversold
CRNX
NASDAQ Healthcare Biotechnology
$34.71
▼ $0.86 (-2.42%)
Mkt Cap: 3.63B
Day Range
$33.40 $35.99
52-Week Range
$24.10 $57.99
Volume
2,137,919
50D / 200D Avg
$45.69 / $39.68
Prev Close
$35.57

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -7.8 0.4
P/B 3.7 2.9
ROE % -40.2 3.8
Net Margin % -6046.2 3.9
Rev Growth 5Y % 63.5 10.0
D/E 0.1 0.2

Key Takeaways

Revenue grew 63.46% annually over 5 years — strong growth
Debt/Equity of 0.05 — conservative balance sheet
Negative free cash flow of -383.68M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 577.25%
Capital intensive — 74.87% of revenue goes to capex

Growth

Revenue Growth (5Y)
63.46%
Revenue (1Y)640.71%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-40.17%
ROIC-37.24%
Net Margin-6046.22%
Op. Margin-6714.77%

Safety

Debt / Equity
0.05
Current Ratio12.32
Interest Coverage0.00

Valuation

P/E Ratio
-7.81
P/B Ratio3.66
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 640.71% Revenue Growth (3Y) 38.48%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 63.46% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 7.70M Net Income (TTM) -465.32M
ROE -40.17% ROA -40.98%
Gross Margin 35.47% Operating Margin -6714.77%
Net Margin -6046.22% Free Cash Flow (TTM) -383.68M
ROIC -37.24% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.05 Current Ratio 12.32
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -7.81 P/B Ratio 3.66
P/S Ratio 472.23 PEG Ratio -0.28
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 3.63B Enterprise Value 3.58B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 7.70M 1.04M 4.01M 4.74M 1.08M
Net Income -465.32M -298.41M -214.53M -163.92M -107.64M
EPS (Diluted) -4.95 -3.69 -3.69 -3.15 -2.80
Gross Profit 2.73M 1.04M 4.01M 4.74M 1.08M
Operating Income -516.77M -338.85M -222.61M -167.88M -107.70M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.14B 1.43B 635.35M 352.18M 351.02M
Total Liabilities 143.41M 109.79M 96.25M 35.85M 19.07M
Shareholders' Equity 992.08M 1.32B 539.11M 316.33M 331.94M
Total Debt 48.54M 51.72M 51.73M 3.08M 3.07M
Cash & Equivalents 101.54M 264.55M 54.90M 32.67M 200.70M
Current Assets 1.05B 1.38B 574.15M 345.18M 344.72M
Current Liabilities 85.07M 59.68M 43.94M 27.72M 16.00M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#14 of 75
76

Recent Activity

Entered Capital Heavy Grower
Mar 24, 2026